Investigation Into JUUL Advertising Launched By Dozens Of State Attorneys General

Most of the nation’s state attorneys general have banded together to launch a joint investigation into the advertising of JUUL cigarettes, which allegedly targeted children and prior non-smokers, fueling the current vaping epidemic among adolescents throughout the United States.

A 39-state coalition is being led by the attorneys general of Connecticut, Florida, Nevada and Texas, and will investigate JUUL Labs, Inc.’s marketing and sales practices over the past few years since the vaping pen was introduced in 2015. They will also investigate the company’s statements on the safety, effectiveness, and risks of using JUUL devices for smoking cessation.

Oregon Attorney General Ellen Rosenblum issued a press release on February 25 announcing the investigation, as did AGs from several other involved states as well.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

“I have long been concerned about how JUUL targets children with their sleek devices and marketing practices. They have almost singled handily gotten a whole new generation of teens hooked on tobacco,” Rosenblum said in the press release. “JUUL’s aggressive advertising has significantly contributed to a public health crisis in Oregon and across the country.”

“Preying on children and those looking for help to quit smoking is the one of the most despicable examples of risking people’s lives for corporate profit,” Nevada Attorney General Aaron Ford added. “I’m proud my office is taking a leadership role in this multistate investigation to get to the bottom of JUUL’s marketing and sales practices.”

JUUL was introduced only a few years ago, but has quickly became the most widely used vaping product among teens, following what critics say was an intentional marketing scheme that promoted the controversial vape pod toward young users, creating new nicotine addictions that are expected to drive JUUL sales for decades.

The addictive JUUL pods are designed to look like USB drives, allowing students to hide their vaping habit from teachers, parents and other adults. Although the manufacturer suggested JUUL was safer than smoking traditional cigarettes, high levels of nicotine are delivered by each pod, making the device particularly addictive.

The new investigation came just days after Pennsylvania filed a complaint against JUUL Labs, alleging their products constituted a public health risk for the state’s citizens, particularly its youth.

The lawsuit indicates JUUL vape pods have caused a public health crisis in Pennsylvania, resulting in a nicotine addiction epidemic allegedly fueled by the manufacturer’s decision to specifically target JUUL advertisements toward teens, children and prior non-smokers, with disastrous results nationwide.

JUUL Vaping Addiction Epidemic

Recent FDA data indicates teen e-cigarette use has reached epidemic levels in the United States, and JUUL Labs has been accused of fueling the growing teen nicotine addiction problems in the United States.

In addition to designing JUUL to look like a USB thumb drive, the manufacturer also marketed and sold JUUL pods in various candy-like flavors, which has resulted in a large number of teens and prior non-smokers starting to vape, and developing addictions to the high levels of nicotine contained in the pods.

In September 2019, the FDA issued a warning letter to JUUL, indicating there was evidence it told school-aged children that its products were safer than cigarettes, which has not been proven.

In addition to this multi-state investigation, a growing number of JUUL lawsuits and class action claims have been filed nationwide. Given similar questions of fact and law raised in complaints brought throughout the federal court system, the JUUL litigation has been centralized before U.S. District Judge William H. Orrick III in the U.S. District Court for the Northern District of California, which is where JUUL Labs, Inc.’s San Francisco headquarters are located.

As JUUL addiction lawyers continue to review and file claims in the coming months, the litigation is expected to continue to grow, and is likely to encompass tens of thousands of complaints.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 2 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 3 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 4 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.